Abstract
AbstractTwo different methods (reduction mediated and carbonyl labelling) for conjugating 188Re to an anti‐tumour monoclonal antibody are described. The radioimmunoconjugates produced were analysed for stability, immunoreactivity, specificity and homogeneity. This indicated that although the two conjugates were comparable in terms of specificity and homogeneity, the carbonyl labelled preparation was more stable. Tumour localisation of both conjugates was confirmed in an ex vivo model of bladder cancer. It is concluded that although both radioimmunoconjugates have potential for intravesical therapy of bladder cancer, carbonyl labelling may offer a method with increased stability.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Labelled Compounds and Radiopharmaceuticals
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
